Novel Pure αVβ3 Integrin Antagonists That
Do Not Induce Receptor Extension, Prime the Receptor, or Enhance Angiogenesis
at Low Concentrations
Posted on 2019-08-16 - 16:04
The
integrin αVβ3 receptor has been implicated in several
important diseases, but no antagonists are approved for human therapy.
One possible limitation of current small-molecule antagonists is their
ability to induce a major conformational change in the receptor that
induces it to adopt a high-affinity ligand-binding state. In response,
we used structural inferences from a pure peptide antagonist to design
the small-molecule pure antagonists TDI-4161 and TDI-3761. Both compounds
inhibit αVβ3-mediated cell adhesion to αVβ3
ligands, but do not induce the conformational change as judged by
antibody binding, electron microscopy, X-ray crystallography, and
receptor priming studies. Both compounds demonstrated the favorable
property of inhibiting bone resorption in vitro,
supporting potential value in treating osteoporosis. Neither, however,
had the unfavorable property of the αVβ3 antagonist cilengitide
of paradoxically enhancing aortic sprout angiogenesis at concentrations
below its IC50, which correlates with cilengitide’s
enhancement of tumor growth in vivo.
CITE THIS COLLECTION
DataCite
3 Biotech
3D Printing in Medicine
3D Research
3D-Printed Materials and Systems
4OR
AAPG Bulletin
AAPS Open
AAPS PharmSciTech
Abhandlungen aus dem Mathematischen Seminar der Universität Hamburg
ABI Technik (German)
Academic Medicine
Academic Pediatrics
Academic Psychiatry
Academic Questions
Academy of Management Discoveries
Academy of Management Journal
Academy of Management Learning and Education
Academy of Management Perspectives
Academy of Management Proceedings
Academy of Management Review
Li, Jihong; Fukase, Yoshiyuki; Shang, Yi; Zou, Wei; Muñoz-Félix, José M.; Buitrago, Lorena; et al. (2019). Novel Pure αVβ3 Integrin Antagonists That
Do Not Induce Receptor Extension, Prime the Receptor, or Enhance Angiogenesis
at Low Concentrations. ACS Publications. Collection. https://doi.org/10.1021/acsptsci.9b00041
or
Select your citation style and then place your mouse over the citation text to select it.
SHARE
Usage metrics
AUTHORS (28)
JL
Jihong Li
YF
Yoshiyuki Fukase
YS
Yi Shang
WZ
Wei Zou
JM
José M. Muñoz-Félix
LB
Lorena Buitrago
Jv
Johannes van Agthoven
YZ
Yixiao Zhang
RH
Ryoma Hara
YT
Yuta Tanaka
RO
Rei Okamoto
TY
Takeshi Yasui
TN
Takashi Nakahata
TI
Toshihiro Imaeda
KA
Kazuyoshi Aso
YZ
Yuchen Zhou
CL
Charles Locuson
DN
Dragana Nesic
MD
Mark Duggan
JT
Junichi Takagi
KEYWORDS
antagonists TDI -4161compoundIC 50Low ConcentrationsTDI -3761.α V β3-mediated cell adhesionhigh-affinity ligand-binding stateNovel Pure α V β3 Integrin Antagonistsα V β3 antagonist cilengitideInduce Receptor ExtensionX-ray crystallographysmall-molecule antagonistselectron microscopybone resorptionpeptide antagonistEnhance Angiogenesisintegrin α V β3 receptortumor growthα V β3 ligandsantibody binding